# Mebendazole and TP53

For the broader mechanism set, start with [Mebendazole Anticancer Mechanisms](/myhealingcommunity-docs/off-label-drugs-for-cancer/mebendazole-in-oncology/anticancer-mechanisms.md).

The short version is:

**Mebendazole does not appear to require intact p53 for its core anticancer activity.**

That makes it different from [Fenbendazole and TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/fenbendazole-and-tp53.md), where p53 status appears more central to the best-known mechanism.

### Why TP53 still matters here

TP53 still helps explain **how** mebendazole is working in a given tumour.

In some models, mebendazole can stabilise p53 and increase p53-linked signals such as **p21** and **MDM2**.

In other models, it still causes cell-cycle arrest and apoptosis when p53 is mutant or absent.

That means TP53 is still biologically relevant.

It just does not look like a strict gatekeeper for baseline activity.

### What the data suggest

#### Activity across wild-type, mutant, and null settings

In ovarian cancer models spanning **wild-type, mutant, and null p53**, mebendazole inhibited growth and induced apoptosis across all three backgrounds.

Mechanistic work in that study supported **p53-independent** p21 induction alongside microtubule depolymerisation.

The authors concluded that the high TP53-mutation rate in ovarian cancer should not automatically block clinical interest in mebendazole.

#### Both p53-dependent and p53-independent routes

A broader repurposing review describes mebendazole as capable of acting through both **p53-dependent** and **p53-independent** routes.

In some lung-cancer models, it stabilised p53 and increased p21 and MDM2.

In p53-null cells, it still triggered cytochrome-c release, caspase activation, and PARP cleavage.

That is apoptosis without requiring p53.

#### Context-dependent p53 engagement

In diffuse midline glioma models, mebendazole induced G2/M arrest and apoptosis across different TP53 backgrounds.

Some models also showed p53 phosphorylation or upregulation.

That points to **context-dependent p53 engagement**, not strict p53 dependence.

### How this differs from fenbendazole

The practical contrast is simple.

Fenbendazole looks more favourable when tumour p53 remains functional.

Mebendazole looks broader.

Its main mechanism set starts with **tubulin disruption**, then extends into cell-cycle arrest, apoptosis, angiogenesis pressure, and pathway effects that have been shown in **p53-wild-type, mutant, and null** settings.

So a somatic TP53 mutation is **not** a clear reason to dismiss mebendazole.

### Practical interpretation

* **TP53 loss or mutation is not a clear disqualifier.**
* **Somatic TP53 still helps interpret pathway mix and response logic.**
* **Tumour type still matters more than gene status alone.**

If you are trying to interpret a report, start with [Somatic TP53](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/somatic-tp53.md) and the wider [TP53 in Cancer Overview](/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/tp53-in-cancer-overview.md).

That section explores how different drugs and natural compounds may be influenced by TP53 status, or may influence TP53-related biology.

### Bottom line

Mebendazole appears much less dependent on functional p53 than fenbendazole.

It can engage p53 pathways when p53 is present.

But its core anticancer activity has also been shown in **mutant** and **null** p53 settings.

### Key references

Mebendazole as a Candidate for Drug Repurposing in Oncology\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC6769799/>

Mebendazole induces apoptosis by targeting ABCB1 and p53-independent p21 in ovarian cancer\
<https://pmc.ncbi.nlm.nih.gov/articles/PMC8820236/>

Anti-tumor effect of mebendazole in diffuse midline glioma cells with H3K27M mutation\
<https://e-century.us/files/ajcr/15/6/ajcr0163760.pdf>

{% hint style="warning" %}
This information is for education only. It is not medical advice, diagnosis, or treatment. Please speak with a qualified clinician before making changes to care, medication, or supplement use.
{% endhint %}

{% hint style="info" %}
© 2026 Abbey Mitchell. All rights reserved. Please share by URL rather than copying page text.
{% endhint %}


---

# Agent Instructions: Querying This Documentation

If you need additional information that is not directly available in this page, you can query the documentation dynamically by asking a question.

Perform an HTTP GET request on the current page URL with the `ask` query parameter:

```
GET https://myhealingcommunity.gitbook.io/myhealingcommunity-docs/testing-monitoring-and-biomarkers/tp53-in-cancer/mebendazole-and-tp53.md?ask=<question>
```

The question should be specific, self-contained, and written in natural language.
The response will contain a direct answer to the question and relevant excerpts and sources from the documentation.

Use this mechanism when the answer is not explicitly present in the current page, you need clarification or additional context, or you want to retrieve related documentation sections.